☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Valneva
Valneva Reports EMA Acceptance of VLA1553 for Chikungunya
November 27, 2023
Valneva and Pfizer Report P-II Study (VLA15-221) Results of VLA15 for Lyme Disease in Pediatric and Adolescent
September 7, 2023
Valneva Reports P-III (VLA2001-301) Cov-Compare Study Results of VLA2001 (COVID-19 Vaccine) for COVID-19
August 30, 2022
Valneva and Pfizer Report Results of VLA15 in P-II (VLA15-221) Trial for the Treatment of Lyme Disease
April 26, 2022
Valneva Received MHRA’s Conditional Marketing Authorization for its Inactivated COVID-19 Vaccine
April 15, 2022
Valneva Reports Completion of VLA1553 in P-III (VLA1553-301) Trial for the Treatment of Chikungunya
March 8, 2022
Load more...
Back to Home